Bimekizumab Response Maintenance to 48 Weeks in Patients With Moderate to Severe Hidradenitis Suppurativa: Pooled Responder Analysis from the Phase 3, Double-Blind, Placebo-Controlled, Randomized Clinical Trials BE HEARD I and II. J of Skin 2024, 8 (2), s396. https://doi.org/10.25251/skin.8.supp.396.